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Abstract
Background and aims: The National UK IBD audit tool is an electronic database created to
improve the quality and safety of care for IBD patients by auditing individual patient care, service
resources and organisation against national standards. We used the National UK IBD audit tool to on 09 O
ctober 2019compare the organisation and process of IBD care between services in Oxford (UK) and Milan
(Italy), as a pilot study to evaluate its application outside national boundaries.
Methods: Clinical and demographic data of patients with CD and UC, consecutively admitted
during a 2 month period, were collected and compared between the centres, to each other and
to the UK IBD standards obtained by previous audit analyses performed in Oxford in 2006.
Results: 20 and 26 patients with UC were admitted in Oxford and Milan, as well as 21 and 20
patients with CD, respectively. Most admissions in Milan were planned admissions for moderately
active treatment-refractory disease. No patient died. Oxford had a higher surgery rate.
Endoscopy for UC consisted mainly of colonoscopy in Milan (92%) and flexible sigmoidoscopy in
Oxford (64%). In CD, Oxford data revealed a higher use of immununomodulators and CT scan,
compared with higher use of bowel ultrasound in Milan. CRP was the preferred biomarker ofy was presented as a highly commended poster at the 4th Congress of ECCO, Hamburg, 2009.
logy Unit, Luigi Sacco University Hospital, Via G.B. Grassi 74, 20157 Milan, Italy. Tel.: +39 0239042486;
ibero.it (A. Cassinotti).
9 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
292 A. Cassinotti et al.disease activity. The following areas did not reach the standards set for the 2006 UK IBD Audit:
the lack in Milan of IBD specialist nurses and few dietitian visits, as well as little attention to
heparin prophylaxis and abdominal radiography in UC. Both sites paid little attention to stool
cultures and revealed a high rate of active smokers in CD and little attention to bone protection
in steroids users. Since the 2006 audit in Oxford, improvements include IBD specialist nurse visits,
dietitian visits, number of active smokers, stool samples, prophylactic heparin, bone protection
and nutritional assessment.
Conclusions: Consistent procedural differences between Oxford and Milan identified by audits of
both UC and CD could be resolved by organisational change, with an improvement in the service.
The UK IBD audit tool is an easy instrument to assess the processes and outcomes of care delivery
in IBD and can be applied also outside UK.
© 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. D
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Inflammatory bowel diseases (IBD) are a group of chronic,
relapsing–remitting, inflammatory conditions which include
Crohn's disease (CD) and ulcerative colitis (UC). 1,2 Together,
they affect about 200–400/100,000 of people, with a higher
rate in England than in southern Europe. 3,4 They present in
late adolescence or early adult life so typically affect people
who are trying to earn a living and/or raise a family and affect
work productivity. 5 At least 80% of CD patients need surgery
at some time, as do 25% of patients with UC. There are many
admissions each year for exacerbations of IBD and admissions
are still associated with mortality. Many deaths occur around
the time of surgery and data indicate that young people are
disproportionately represented amongst those deaths. 6,7
The British Society of Gastroenterology (BSG) and the Euro-
pean Crohn's and Colitis Organisation (ECCO) have published
evidence-based guidelines that cover all the clinical aspects of
management of IBD. 8–10 These can be used as standards of care
to audit the local management of IBD. An audit should seek to
improve the quality and safety of care for patients by auditing
individual patient care, service resources and organisation,
against defined standards.
The UK IBD Audit was the first UK-wide audit performed
within gastroenterology. The first round was conducted from
September 2006 to December 2006: 281 acute hospitals that
admit patients with IBD in England, Northern Ireland,
Scotland and Wales used the audit tool and a final report
on outcomes and planned targets for a re-audit was
published (http://ibdaudit.rcplondon.ac.uk/2006/ Appen-
dix 1). Audit of IBD practice is not widely used in other
countries and the UK IBD audit tool has never been validated
outside the UK. Consequently, we have compared IBD care in
this pilot study between two centres in Oxford (UK) and Milan
(Italy), using the National UK IBD audit tool, to evaluate its
application outside national boundaries.
2. Methods
The study was approved by our Institutional Review Board.
Organisational, clinical and demographic data of patients
with IBD consecutively admitted during a two month period
(Feb–Mar 2008 in Milan, Apr–May 2008 in Oxford) were
collected and compared between the centres, to each other
and to the UK IBD standards obtained by previous audit
analyses performed in Oxford in 2006 (Appendix 1).The UK IBD audit tool consists of four parts. The first
concerns the structure of hospital IBD services, analysing
inpatient activity, organisation of care, interaction between
hospitals and patient groups, and IBD support services. The
other three sections (UC inpatients, CD inpatients, and CD
outpatient care) require specific clinical and demographic
data of patients to be entered during the observation period.
The audit tool is web-based and includes context-specific
online help, including definitions and clarification of terms,
internal logical data checks and feedback to enable
complete and accurate data. Security and confidentiality
were maintained through the use of site-specific codes.
Proformas were accessed using unique identifiers and pass-
words, with data saved during, as well as at the end of an
input session. To assess patient care, the aim was to audit at
least 40 consecutive inpatient case notes (at least 20 CD and
20 UC) at each centre in late spring of 2008.
2.1. Statistical analysis
An explorative statistical analysis was performed. Differences
in management and outcomes were identified by comparing
proportions of each event within classes of categorical
variables using Pearson chi-squared statistic or Fisher's exact
test when appropriate. p values, when less than 0.05, were
reported. No attention was paid to multiplicity of tests
problem, since the analysis was judged just as a screening
procedure, and considering significant p values only as flags.
3. Results
The complete results of each audit section are presented in
Tables 1–3. After a general presentation of the sites, below
we focus on the potential key messages from a comparison of
the results between Oxford and Milan, as well as between
current (2008) and previous (2006) results in Oxford, in order
to assess if they met the standards.
3.1. Organisation and structure of hospital
IBD services
General hospital demographics were similar (Table 1). Both
hospitals had a dedicated gastroenterology ward, with 4 beds
per lavatory in Oxford and 2 beds per lavatory in Milan (vsmax
3 recommended beds in the 2006 standards).
Table 1 Organization and structure audit questions and results.
Question Oxford 2006 Oxford 2008 Milan 2008
General Hospital Demographics
Total No. of beds 528 874 604
Presence of an acute medicine unit Yes Yes Yes
Presence of an acute surgical unit Yes Yes Yes
Presence of an Intensive Therapy Unit on site Yes (14 beds) Yes (16 beds) Yes (20 beds)
Presence of a High Dependency Unit on site No No Yes
Inpatient Activity
No. of patients discharged with a primary diagnosis of UC (2 months) Not comparable 20 26
No. of patients discharged with a primary diagnosis of CD (2 months) Not comparable 21 20
No. of patients operated for UC Not comparable 7 2
No. of patients operated for CD Not comparable 19 5
Ileo-anal pouch surgery performed on site Yes Yes Yes
Gastroenterology Services
Presence of a dedicated Gastroenterology ward Yes Yes Yes
No. of beds per lavatory on the ward 3.1 4 2
No. of WTE Gastroenterologists 2.9 4 5.5
No. of SpRs+No. of associate specialists 4+0 4+4 5+2
No. of IBD Nurse Specialists 0 1 0
No. of sessions/week of Specialist Nurse time dedicated to IBD care NA 10 NA
Colorectal Services
No. of Colorectal Surgeons 4 4 2
No. of Colorectal SpR+No. of Colorectal Associate specialists 4+0 6+0 3+2
No. of Stomatherapy Nurses 5 5 2
No. of sessions/week of Stomatherapy Nurse time dedicated to stoma care 40 40 5
Multidisciplinary Working
Presence of a searchable database of IBD patients Yes Yes Yes
Timetabled meetings taken place between: Gastro & colorectal surgeons?
Gastro & pathologists?
Gastro & radiologists?
Colorectal surgeons & pathologists?
Colorectal surgeons & radiologists?
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Presence of a specialist GI Pathologist Yes Yes Yes
Presence of a specialist GI Radiologist Yes Yes Yes
Dietetics and Nutritional Services
Presence of a hospital nutrition team Yes Yes Yes
Is it a multidisciplinary team? Yes Yes No
Does the team conduct ward rounds? Yes Yes No
If, yes how frequently? Daily Daily NA
Number of dietetic sessions/week dedicated to GI disorders 24 10 On demand
Outpatient Services
Written information on whom to contact in the event of a relapse Yes Yes Yes
Latency to be visited after a relapse b7 days b7 days b7 days
Methods of contact to an IBD specialist Telephone Telephone
e-mail
Telephone
e-mail
Presence of joint or parallel clinics between Gastroenterologists and
Surgeons
Parallel Parallel Joint
Patient Information
Written information about IBD? Yes Yes Yes
Monitoring of established immunosuppresive therapy
Monitoring established immunosuppresive therapy Combination
of primary and
secondary care
monitoring
Combination
of primary and
secondary care
monitoring
Combination
of primary and
secondary care
monitoring
IBD Support Services
Presence of a paediatric to adult handover clinic for young patients with IBD Yes Yes Yes
Presence of a psychologist attached to the Gastroenterology service? No No No
Presence of an acute pain management team Yes Yes Yes
(continued on next page)(continued on next pa )
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Table 1 (continued)
Question Oxford 2006 Oxford 2008 Milan 2008
Management of Ulcerative Colitis
Written trust guidelines for the management of acute or severe colitis Yes Yes Yes
Interactions between your hospital and patients and patient groups
Open forums or meetings for patients with IBD Yes, every
4–8 months
Yes, every
4–8 months
Yes, every
8–12 months
Are any of the following activities or systems in place to involve patients
in giving their views on the development of your IBD services?
Individual
patient
representatives
Individual
patient
representatives
Regular patient
surveys
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initial audit in 2006, an IBD specialist nurse positions had
been created in Oxford, while they do not exist yet in Milan.
Moreover, Milan had a lower number of stomatherapy nurses
(2 vs 5). Both sites had a searchable database of IBD patients,
as well as timetabled meetings between colorectal surgeons
and gastroenterologists, pathologists and radiologists. In
contrast, there were no timetabled meetings in Milan
between gastroenterologist and pathologists or radiologists,
although both sites had at least one specialist gastrointes-
tinal pathologist and radiologist. Both centres had a dietitic
service, while only Oxford had a multidisciplinary nutritional
team conducting daily ward rounds.
There was similar organisation for patients to contact the
centre at both sites, to guarantee a clinic appointment within
7 days. Both centres made available written information about
IBD and therapies, as well as organising periodic meetings with
patients and scientific congresses. There were no psychologists
attached to either gastroenterology service. Outpatient clinics
were organised to run in parallel between gastroenterologists
and colorectal surgeons in Oxford, while Milan conducted joint
clinics between the two disciplines each week for patients
suitable for surgical problems and treatments.
3.2. Ulcerative colitis inpatients
All data on the audit of inpatients with a primary diagnosis of
UC are summarised in Table 2. p values are reported when
less than 0.05.
3.2.1. Reason for, route of admission and outcome
Twenty (60%male, median age 45, range 28–73 years) and 26
(42% male, median age 41, range 18–85 years) consecutive
patients with UC were enrolled in Oxford and Milan,
respectively. The reasons and route of admission differed,
with more patients with severe disease, more patients
having elective surgery, and more tertiary referrals being
admitted to Oxford. No patient died and the median duration
of hospitalization was similar in both centres.
3.2.2. Assessment of disease
All patients (even tertiary referrals) were already known to
both centres. As might be expected from the different routes
and reasons for admission, Oxford patients were slightly
sicker, with a higher number of bowel movements/day, CRP
and highest recorded pulse rate and temperature, but
differences did not reach statistical significance. ESR levels
were similar between Oxford and Milan, but ESR wasmeasured in only 6 (30%) of Oxford patients, but 25 (96%)
in Milan (p=0.000).
Stool samples for Clostridium difficile toxin (CDT) and
standard stool cultures were sent in 71% of patients in Oxford,
comparedwith 38% in 2006 (p=0.003) and 57% in Milan (p=NS.),
within a median of 0 and 1 days, respectively. Endoscopic
assessment was performed in all patients in Milan (96% vs 64%,
p=0.007), where all procedures were full colonoscopy, com-
pared to flexible sigmoidoscopy in all Oxford cases, probably
reflecting the difference between elective and emergency
admission. Median latency to endoscopy was similar in Milan vs
Oxford (1–2 days, maximum 7 days). Nevertheless, the severity
of mucosal disease was similar in both centres. Biopsies were
taken in 89% of cases in Oxford and 100% in Milan, with the
histopathology report available after similar intervals (median
4–5 days), except for 1exceptional caseat eachcentre, delayed
for 14–18 days.
3.2.3. Post-admission monitoring
Stool frequency was monitored daily in all patients at both
sites (vs 31% Oxford 2006; p=0.008). Pulse and temperature
were measured 1–3 times/day in Milan and at least 4 times
daily in the current Oxford audit. CRP was monitored every
2–3 days in most patients. On the other hand, ESR was re-
checked once in Milan in 77%, but in only 29% in Oxford
(p=0.003). A plain abdominal radiograph was less frequently
performed in Milan (23% vs 86%; pb0.001), reflecting a
difference in disease severity.
3.2.4. Medical treatment
Most patients received intravenous or oral corticosteroids.
Hydrocortisone was the steroid of choice in Oxford, but it
was methylprednisolone in Milan. Steroids were given sooner
in Oxford than in Milan (median 0, range 0–7 days, vsmedian
4, range 0–13 days), where the results of disease assessment
by colonoscopy were usually awaited before starting
steroids. Almost all Oxford patients (95%) received prophy-
lactic heparin, compared to only 19% in Milan (p=0.000),
possibly reflecting differences in disease activity and indica-
tion for admission.
After failure of intravenous steroids, ciclosporin (CsA) 2 mg/
kgwas used in 3 patients, infliximab (IFX) in 2 patients inOxford.
Surgery was performed in 4 cases. In Milan, CsA 4 mg/kg was
used in1patient and IFX in1, butnooperationswereperformed.
3.2.5. Surgical and other therapy
Data on surgical interventions are not comparable, since no
operations were performed during the audit period in Milan,
Table 2 Ulcerative colitis audit questions and results.
Question Oxford
2006
Oxford
2008
P Oxford
2006 vs
2008
Milan P Milan vs
Oxford 2008
Reason for, route of
admission and outcome
Source of admission:
General Practitioner
Accident & Emergency
Outpatients Department
Other hospital
Not documented
19%
–
57%
5%
19%
10%
10%
60%
20%
–
0.013 –
8%
92%
–
–
0.008
0.000
Reason for admission:
Emergency, active UC
Planned, active UC
Elective for surgery
57%
19%
24%
65%
5%
30%
8%
92%
–
0.000
0.000
Speciality responsible
for the patient's initial care:
Acute Medicine
Gastroenterology
Colorectal Surgery
Geriatrics, General Medicine,
General Surgery
6%
81%
13%
–
7%
71%
21%
–
–
100%
–
0.004
0.014
IBD specialist nurse's visit 25% 100% 0.000 – 0.000
Deaths 0 0 0
Duration of hospitalization
(days; median, range)
7 10 (1–25) 7 (4–22)
Assessment of disease No. of stools (median, range) 5.5 8 (2–30) 5 (2–10)
Pulse rate (median, range) 86 93
(64–150)
79
(60–110)
Temperature (°C; median,
range)
37.1 37
(35.9–38.8)
36.5
(36.4–38.5)
CRPN5 mg/L 75%
median 109
86%
median 88
73%
median 23
Hb (g/dl; median, range) 12.5 12 (9–15.5) 12 (9–14.4)
ESR (median, range).
nd=not documented
13 24 (5–49)
nd=70%
30 (5–78)
nd=4%
0.000
Stool sample for Standard Stool
Culture and CDT
38% 71% 0.003 57%
Latency to stool sample (days;
median, range)
1 0 (0–1) 1 (0–20)
Endoscopy: Rigid Sigmoidoscopy
Flexible Sigmoidosc.
Colonoscopy
None of the above
–
44%
–
56%
–
64%
–
36%
–
–
96%
4%
0.000
0.000
0.007
Latency to endoscopy (days;
median, range)
2 1 (0–7) 2 (0–6)
Endoscopic activity: Mild
Moderate
Severe
14%
29%
57%
11%
44%
44%
4%
56%
40%
Biopsies taken 100% 89% 100%
Latency to histology (days;
median, range)
4 5 (0–14) 4 (2–18)
Post-admission
monitoring
Prophylactic heparin 81% 95% 19% 0.000
Pulse monitoring: 4 or more
times/day
1 to 3 times per day
bonce per day
not monitored
44%
50%
–
6%
100%
–
–
–
8%
92%
–
–
Tachycardia (N90 bpm) – 7% –
Temperature monitoring: 31% 100% 0.0000 –
(continued on next page)(continued on next page)
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Table 2 (continued)
Question Oxford
2006
Oxford
2008
P Oxford
2006 vs
2008
Milan P Milan vs
Oxford 2008
4 or more times/day
1 to 3 times per day
bonce per day
63%
–
–
–
100%
–
FeverN37.5 °C 7% 14% 4%
Stool frequency monitoring: Daily
Every 2 to 3 days
Every 4 to 6 days
Once
Not monitored
63%
–
–
–
38%
100%
–
–
–
–
0.008 92%
8%
–
–
–
CRP monitoring: Daily
Every 2 to 3 days
Every 4 to 6 days
Once
Not documented
31%
56%
6%
–
6%
36%
57%
–
7%
–
8%
62%
19%
12%
–
ESR monitoring: Daily
Every 2 to 3 days
Every 4 to 6 days
Once
Not documented
–
6%
–
44%
50%
–
–
–
29%
71%
11%
8%
4%
77%
–
0.003
Plain abdominal x-ray 88% 86% 23% 0.001
Discharge arrangements Appointments to: Gastroenterologist
Colorectal surgeon
71%
43%
65%
60%
100%
12%
0.001
0.000
Oral steroids on discharge 71% 45% 15% 0.027
Steroid reduction programme
started
100% 100% 100%
Bone protection agents 7% 56% 0.000 50%
Post-admission
monitoring
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All patients at both sites received an appointment for follow
up in the gastroenterological or surgical outpatient clinic;
65% received an appointment to gastroenterology and 60% to
colorectal surgical clinics in Oxford, vs 100% (p=0.001) and
12% (pb0.001), respectively, in Milan. Follow up appoint-
ments to both a gastroenterologist and a surgeon was given
to 25% of Oxford patients and to 11% of Milan patients
(p=NS), reflecting the different types of admission. A steroid
reduction programme was started on discharge in all
patients, but bone protection agents were prescribed in
only 56% of cases in Oxford (vs 7% in 2006; p=0.000) and in
50% in Milan (p=NS).
3.3. Crohn's disease inpatients
All data on the audit of inpatients with a primary diagnosis of
CD are summarised in Table 3. Significant differences be-
tween centres are reported with p values.3.3.1. Reason for, route of admission and outcome
Twenty-one (24% male, median age 37 (range 18–68) years)
and 20 (40%male,median age 48 (range 18–70) years) patients
with CDwere admitted in Oxford and Milan, respectively. Most
admissions (70%) in Milan were medical elective (vs 24% in
Oxford; p=0.003), mainly from the OPD (75% vs 42%;
p=0.003), with a similar rate of emergency admissions and
no tertiary referrals during the audit period.
There was a longer duration of symptoms (new or relapse)
precipitating admission forMilan,with 40%of patients admitted
after 8 weeks of symptoms onset (vs 17% in Oxford; p=0.036). A
higher proportion of audited patients were being admitted for
elective surgery in Oxford (43% vs 0%; pb0.001). All patients in
Oxford were also seen by an IBD specialist nurse, which was not
the case in Milan (p=0.000). No patient died and the median
duration of hospitalization was similar at both centres.
A higher proportion of patients in Oxford were taking AZA
on admission (52% vs 20%; p=0.031) andmore were on dietary
therapy (14% vs 0%; p=0.079, NS) than in Milan. Use of other
therapies (mesalazine, antibiotics, corticosteroids and anti-
TNF agents) was similar. Disease extent was similar between
centres, as well as the rate of current smokers, even if too
high (29% vs 30%).
3.3.2. Assessing the severity of Crohn's disease
Symptoms and signs of active CD were similar, except for a
trend towards fewer patients reporting diarrhoea in Milan
Table 3 Crohn's disease audit questions and results.
Question Oxford
2006
Oxford
2008
P Oxford
2006 vs
2008
Milan
P Milan
vs Oxford
2008
Reason for,
route of
admission
and outcome
Primary reason for admission:
Emergency, active CD
Planned, active CD
Elective for surgery
New diagnosis of CD
52%
9%
30%
9%
29%
24%
43%
4%
30%
70%
–
–
0.003
0.000
Source of admission:
General Practitioner
Accident & Emergency
Outpatients Department
Other hospital
Not documented
19%
19%
31%
–
31%
17%
33%
42%
8%
–
–
25%
75%
–
–
0.003
Speciality responsible for
the initial patients care
Acute medicine
Gastroenterology
Surgeons (Colorectal+General)
General medicine
6%
50%
38%
6%
8%
25%
50%
17%
5%
80%
10%
5%
0.000
0.033
IBD specialist nurse's visit 6% 100% 0.000 – 0.000
Deaths 0 0 0
Duration of hospitalization
(days;median, range)
7 8 (3–28) 9 (5–19)
Treatment on admission:
5-ASA
AZA
MP
MTX
Antibiotics
Corticosteroids
Dietary therapy
Anti-TNF
None
22%
43%
4%
9%
–
30%
–
–
30%
19%
52%
–
10%
10%
10%
14%
10%
24%
25%
20%
–
–
5%
5%
–
10%
45%
0.031
Current smokers
nd=not documented
43%
9%
29%
24%
30%
10%
Assessing the severity of
Crohn's disease
Diarrhoea 63% 67% 35% 0.033
Stool No. (median, range) 4 6 (1–15) 5 (3–7)
Pulse rate (median, range) 91 87 (62–110) 79 (60–92)
Temperature (°C, median,
range)
36.9 37 (36.5–38.6) 37 (36.4–37.5)
FeverN37.5 °C 6% 17% 20%
CRPN5 mg/L 81%
(median 35)
83%
(median 68)
65%
(median 21)
Hb (g/dl; median, range) 12.8 11 (9.1–14.3) 12 (6.1–14.5)
ESR (median, range)
nd = Not Documented
19 44 (7–80)
nd=50%
18 (10–10)
nd=14%
0.025
Stool sample for Standard
Stool and CDT Culture
30% 75% 0.009 57%
Latency to stool sample
(days; median, range)
0–2 1 (0–2) 1 (0–7)
Abdominal Ultrasound Scan 30% 5% 85% 0.000
Abdominal CT Scan 17% 29% 5% 0.045
Patient's weight measured 50% 100% 100%
BMI measured 25% 100% 75%
Dietitian's visit 44% 91% 15% 0.000
Dietary treatment 31% 100% 25% 0.000
Prophylactic herapin 74% 100% 10% 0.000
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Table 3 (continued)
Question Oxford
2006
Oxford
2008
P Oxford
2006 vs
2008
Milan
P Milan
vs Oxford
2008
Medical
interventions
Corticosteroids: Intravenous
Oral
None
81%
–
19%
58%
–
42%
5%
5%
90%
0.000
0.000
Type of steroids: Prednisolone
Budesonide
Hydrocortisone
–
–
100%
–
–
100%
100%
–
–
Latency to steroids
(days; median, range)
0 (0–5) 4 (0–7)
Blood transfusion 17% 5% 5%
Anti-TNFα therapy 14% 5% –
Surgery Not available 67% 5% 0.000
Discharge arrangements Appointments to:
Gastroenterologist
Colorectal Surgeon
74%
48%
90%
76%
100%
35%
0.008
Oral steroids on discharge 61% 33% 5% 0.022
Steroid reduction programme
started on discharge
79% 100% 100%
Bone protection agents 14% 29% –
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of obstructive symptoms. On the other hand, Oxford cases
included sicker patients, as reflected by higher temperature,
median CRP and ESR levels, although ESR was less used in
Oxford (50% vs 86%; p=0.025). Stool was sent for standard
culture and CDT assay in 75% of cases in Oxford (vs 30% in
2006; p=0.009) and 57% in Milan (p=NS), with a latency of up
2 and 7 days, respectively (median 1 day). Abdominal ultra-
sound was the initial imaging method of choice in Milan (85%
vs 5%; pb0.001), compared with CT in Oxford (29% vs 5%;
p=0.045).
All patients had their weight measured, but Oxford paid
more attention to nutritional assessment, with BMI measured
in 100% (vs 75%; p=0.059, NS) and dietitian visits in 91% (vs
15%; pb0.001).
Prophylactic use of heparin was reported in 100% of Oxford
inpatients with CD, but only in 10% of Milan cases (pb0.001).
3.3.3. Medical interventions
Oxford used corticosteroids more often, consistent with
higher disease activity (58% vs 10%; pb0.001), given after a
median latency of 0 (range 0–5) days (vs 4, range 0–7). Anti-
TNF agents were used in only 5% of inpatients in Oxford and in
no patients in Milan (p=NS), but that reflects their normal
use in the outpatient setting. The audit tool did not allow
data collection on planned post-admission infliximab.
3.3.4. Surgical interventions
More Oxford patients had surgery (67% vs 5%; pb0.001)
during the admission, but this reflects elective admissions as
well as sicker patients, while not allowing for the practice of
deferring surgery to elective readmission after initial
discharge. Indications for surgery and the type of interven-
tion were more widely represented in Oxford; laparoscopic
procedures were performed in 21% of Oxford, but 5% in Milan.ASA status was reported in 43% of patients in Oxford and in no
cases in Milan. Written reports by a stoma nurse were made
in 93% of cases in Oxford (vs 0%; p=0.008).
3.3.5. Discharge arrangements
On post-operative discharge, AZA was introduced in 36% of
cases in Oxford, but 50% of patients did not receive any drug.
All patients received a follow up appointment with a gastro-
enterologist (90% vs 100%; p=NS) or a colorectal surgeon
(76% vs 35%; p=0.008), with 67% of patients in Oxford
receiving appointments to both a gastroenterologist and a
surgeon (vs 35%, p=0.042). All steroid users received a
steroid reduction programme, but only 29% of cases in Oxford
and no patients in Milan received bone protection agents
(p=NS, also vs Oxford 2006).4. Discussion
Clinical audit is the process formally introduced in 1993 into
the United Kingdom's National Heatlh Service (NHS) as a
quality improvement process that seeks to improve patient
care and outcomes, through systematic review of care
against explicit criteria and the implementation of change.
The key component of clinical audit is that performance is
reviewed (or audited) to ensure that what should be done is
being done and (if not) it provides a framework to enable
improvements to be made. The component parts of a clinical
audit are: setting standards, measuring current practice,
comparing results with standards (criteria), changing practice,
and then re-auditing to make sure practice has improved. This
process is known as the audit cycle. As might be expected, re-
auditing is the phase of the cycle that most commonly lapses.
The UK IBD audit tool is a collaborative partnership
between gastroenterologists (the British Society of
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Coloproctology of Great Britain and Ireland), patients (the
National Association for Colitis and Crohn's Disease) and
physicians (the Royal College of Physicians of London). After
the first audit cycle in 2006, a list of IBD standards were
reported (Appendix 1), which we have used to complete the
cycle by re-auditing Oxford IBD practice in 2008 and to
compare it with IBD management in Milan. This has allowed us
to make some interesting observations.
Concerning the organisation of IBD care, Oxford has
improved its standards since the initial audit in 2006, by
introducing IBD specialist nurses. In contrast, Milan should be
encouraged to create this important position and to organise
multidisciplinary and nutritional teams. Both ensured immedi-
ate access for outpatients to specialist medical or surgical
opinions, but in different ways: Oxford runs parallel clinics so
that one specialist can walk down the corridor to ask a
colleague to see a patient there and then, while Milan runs
joint clinics in dedicated sessions of the week, with both
specialists in the same consultation. Neither centre met the
standard that psychologists should be attached to the
gastroenterology service.
It is however, outcomes, rather than the organisation of
care, that matters most. Some differences between the two
centres reflect the different types of patients admitted more
than the clinical approach. The duration of hospital stay was
similar between centres, but patients with either UC or CD
appeared somewhat sicker on admission to Oxford, although
the number of patients is small. For disease activity
assessment and monitoring, CRP is the preferred biopara-
meter, 11 although measurement of the ESR is still embedded
in some objective activity indices and therefore included in
guidelines. 9,10
In UC a significant difference between the 2 centres is the
endoscopic approach to disease assessment. In Milan
procedures always consist of full colonoscopy, in order to
(re)assess disease activity, extent and exclude unexpected
pathology. 12 These data are considered fundamental before
starting treatment, which in turn causes a longer latency
before starting steroid therapy. In contrast, Oxford generally
only uses flexible sigmoidoscopy, partly because they admit
sicker patients with UC rather than elective admissions for
treatment-refractory disease and partly because of easier
access. Furthermore, treatment often started empirically on
the day of admission, pending endoscopic assessment and
endoscopy was not repeated if disease activity had recently
been confirmed in outpatients. This is a matter of debate
between the 2 clinical groups.
According to the 2006 standards for UC, both stool cultures
and CDT assay should be performed in all patients admittedwith
active UC. This remains to be reached at both sites, but there
has been a significant increase in the proportion of assays in
Oxford since the previous audit. Milan rarely uses prophylactic
heparin and uncommonly performs a plain abdominal X-ray on
admission; although this may reflect lower disease severity, the
benefits of such procedures have been reported. 13,14 Imaging in
CD inpatients was initially exclusively performed through bowel
ultrasound in Milan, reflecting local expertise, 15 while CT scan
was the routine method in Oxford. This needs to be debated,
since excessive radiation exposure has been reported, 16 and
expert abdominal US may be sufficient to exclude complica-
tions. Both centres revealed a high rate of active smokers amongpatients with CD, although smoking status was frequently
missing in the clinical case notes, reflecting insufficient atten-
tion to the detrimental effects of smoking on disease prog-
nosis, 17 and the unequivocal benefits of smoking cessation in
CD. 18
The numbers of patients and multiple comparisons mean
that care should be taken not to over-interpret differences,
but this was primarily a feasibility study and to determine
whether the established UK audit tool could be used across
national boundaries. It can. The web-based tool was
accessible and offers the potential for wider application in
Europe, especially since audit analysis is almost unknown in
some countries, including Italy. It demonstrates the value of
periodic re-audit, since there were measurable changes in
practice in Oxford to meet national standards in the 2 years
since the first analysis. Audit makes physicians critically
aware of their clinical practice, in order to change or
improve disease management. Moreover, the validation of
the audit tool in different countries could improve the tool
itself, refining the questions to allow for local organisation
and practice. This is an opportunity for ECCO and improve-
ments on clinical guidelines might be based on audit results.
Statement of authorship
AC collected and interpreted the data, and drafted the
manuscript. SK helped to collect and interpret the data. SA
helped to collect and interpret the data. NM provided surgical
data and helped to interpret the data. GS provided the surgical
data. PF provided the histological data. PD performed the
statistical analysis. BG provided the surgical data. ML provided
the clinical data. GM provided the endoscopic data. BW
provided the histological data. DF helped to interpret the
data.GVhelped to interpret the data.GBPwas the coordinator
of the study in Italy. ST conceived the study, interpreted the
data, drafted the manuscript and was the coordinator of the
study in UK.Conflict of interests
All authors declare they do not have any financial and
personal relationships with other people or organisations
that could inappropriately influence this work.
Acknowledgements
Authors are grateful toMrCalvin DownandDr Keith Leiper of the
UK IBD Audit group for access to the webtool, Helen Small for
clerical assistance and the European Crohn's and Colitis
Organisation (ECCO) for a Travel Award to Dr. Cassinotti to
facilitate interaction between Milan and Oxford.
Appendix 1. UK IBD Audit 2006 National
Report— List of IBD Standards
1) Organisation & Structure of IBD services
General Hospital Demographics: Hospitals where surgery
is performed for IBD should have ITU beds with 24 hr care by
anaesthetists/intensivists on site.
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should have the opportunity to have ileo-anal pouch surgery
either locally, if available, or at a regional centre.
Gastroenterology Services: Specialty triage of emergency
admitted IBD patients to appropriate medical or surgical
gastroenterology. No more than 3 patients per lavatory. At
least 2 WTE Medical Gastroenterologists. At least 1 IBD
specialist nurse with at least 5 sessions dedicated to IBD.
Colorectal Services: At least 2 FTE Colorectal surgeons. At
least 1 stoma-care nurse specialist with at least 5 sessions
dedicated to stoma care.
Multidisciplinary Working: Sites should have a searchable
database to allow adequate audit. A weekly multidisciplinary
meeting should take place between gastroenterologists, colo-
rectal surgeons and radiologists. There should be regular
histopathology conferences (at least 1 per month). Each hos-
pital should have a radiologist and pathologist with a special
interest in gastroenterology.
Dietetics and Nutritional Services: Each site should have a
multidisciplinary nutrition team. This team should conduct
ward rounds at least twice a week. At least 5 dietetic
sessions per week should be dedicated to gastroenterological
diseases (includes inpatients and outpatients).
Outpatient Services: A clear process for telephone access for
ill patients should be established that allows review within one
week. Written information for patients with IBD should be
readily available in clinic areas. Joint or parallel clinics should
exist to discuss and refer patients betweenmedical and surgical
teams.
Patient Information: Written information on IBD should be
provided to each patient with IBD.
Monitoring of established immunosuppresive therapy:
Should be a written policy for the mechanism of monitoring
immunosuppressive therapy.
IBD Support Services: There should be regular (usually 1 or
2 per year) transition clinics involving paediatricians and
adult gastroenterologists for hand over of patients to adult
services. These can be done on a regional basis.
Management of Ulcerative Colitis: Written Trust guidelines
should exist for the management of acute or severe colitis.
Interactions between your hospital and patients and
patient groups: There should be regular meetings (at least
once a year and usually on a regional basis) between groups of
patients with IBD (and their relatives or carers) and hospital
staff, this should involve medical, surgical and nursing staff.
2) Ulcerative Colitis (inpatient)
Admission: Patients should be transferred to the care of a
medical gastroenterologist or colorectal surgeon within 24
hours of admission. Patients should be seen by a consultant
gastroenterologist or colorectal surgeon within 3 days of
admission. Patients should be seen by an IBD specialist nurse
during admission. Patients should be transferred to a specialist
gastroenterology ward.
Severity of Disease: Patients should have stool frequency
documented in first 24 hours of admission. Pulse rate and
temperature to be taken at least 4 times in first 24 hours of
admission. Patients should have haemoglobin, albumin and
CRP (or ESR) performed. Patients with diarrhoea should have
a standard stool culture and CDT performed within 48 hours
of admission.
Endoscopic Assessment: New cases of suspected UC
admitted to hospital should have endoscopic sigmoidoscopyconfirmation within 3 days of admission. Endoscopy report
should contain an assessment of severity. New cases of UC
admitted to hospital should have biopsies taken for histology
and these should be reported within 5 days.
Monitoring of Colitis: Patients should have prophylactic
heparin. Pulse rate and temperature monitored at least 4
times a day. Stool frequency should be monitored daily. ESR,
or CRP should be monitored every 24–48 hours in severely
active ulcerative colitis. Patients should have a plain
abdominal X-ray with 24 hours of admission. If toxic mega-
colon is present the abdominal X-ray should be repeated the
next day if emergency surgery is not undertaken.
Steroid therapy: Appropriate intravenous steroid therapy
(400 mg hydrocortisone or 60 mg methylprednisolone) should
be initiated within 24 hours of admission in a suspected severe
attack of UC. If the attack of colitis is not settling within
72 hours of appropriate steroid therapy the risk of colectomy is
high. If there is no response to appropriate corticosteroids
within 3 days, rescue therapeutic options need to be discussed
with the patient (either surgery, ciclosporin or anti-TNFα
therapy). A consultant colorectal surgeon should discuss the
surgical options with the patient.
Ciclosporin Therapy: Creatinine should be measured within
the 48 hours prior to initiation of ciclosporin. Magnesium and
cholesterol should be measured within the 48 hours prior to
initiation of intravenous ciclosporin. Creatinine and FBC should
be monitored daily. Ciclosporin levels should be checked daily
after 3 days of IV therapy.
Surgical Interventions: Consultant colorectal surgeons
should be involved with the discussion with the patient
regarding the decision to operate. Patients having resectional
surgery for UC should see a stoma nurse prior to the operation.
Operations should be performed or assisted by a consultant
colorectal surgeon. ASA status should be recorded pre-
operatively.
Discharge Arrangements: Patients should be followedupby
a gastroenterologist or colorectal surgeon. Patients discharged
on oral steroids should have a steroid reduction programme
stated on discharge. Patients on oral steroids should be co-
prescribed bone protection agents (such as calcium and vita-
min D or bisphosphonates).
3) Crohn's Disease (inpatient)
Admitting Speciality: Patients admitted with CD should be
under the care of medical gastroenterologists or colorectal
surgeon within 24 hours of admission. Patients should be
transferred to a specialist gastroenterology ward. All pa-
tients should be seen by a consultant gastroenterologist or
colorectal surgeon within 3 days of admission. All patients
should be seen by an IBD specialist nurse during admission.
Smoking Status: Smoking status should be documented
and smoking cessation support should be offered.
Severity of Disease: Patients should have stool frequency
documented in the first 24 hours following admission.
Patients should have haemoglobin, albumin and CRP (or
ESR) performed in the first 24 hours following admission.
Exclusion of Infection: Patients with diarrhoea should
have a standard stool culture and CDT performed within
48 hours of admission. Patients with fever (N37.5 °C on two
occasions) should have blood cultures performed.
Imaging: For suspected abdominal sepsis, imaging should
be performed within 48 hours of request and reported within
24 hours of being done.
301Audit on IBD care using the UK IBD Audit tool
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/article-abstract/3/4/291/472745 by guest oWeight Assessment and Dietetic Support: Patients should
be weighed and BMI calculated. Non-elective admissions
should be seen by a dietician. Nutritional support should be
provided for malnourished patients.
Use of anti-thrombotic therapies: Patients should have
prophylactic heparin.
Blood Transfusion: Patients with a haemoglobin level of
less than 10 g/dL should be considered for blood transfusion
or iron infusion.
Initiation of Treatment with anti-TNF- during admission:
All patients given anti-TNF-α for the first time should have a
chest X-ray within the previous 3 months.
Surgical Interventions: Consultant colorectal surgeons
should be involved with the discussion with the patient
regarding the decision to operate. Patients having resec-
tional surgery for CD should see a stoma nurse prior to
operation. Operation should be performed or assisted by a
consultant colorectal surgeon. Patients should have ASA
status documented prior to surgery.
Post-Operative Prophylactic Therapy: Prophylactic ther-
apy to try to reduce recurrence should be discussed with CD
patients having resectional surgery with anastomosis.
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